Results from the MATTERHORN phase 3 study demonstrate that immunotherapy in combination with standard chemotherapy before and after surgery significantly…
Josep Tabernero
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The…
Published in the journal Nature Communications*, results from a first-in-human, phase I clinical trial of an oral, potent and reversible…
Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…
Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with…
Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has…
First results of two multi-center international Phase 1 dose-escalation and -expansion clinical trials of novel T-cell bispecific antibody cibisatamab as…
Celebrated today at the General Assembly of the Organisation of European Cancer Institutes (OECI), VHIO’s Director and Head of the…
